FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891638336> ?p ?o ?g. }

• W2891638336 abstract "e16005 Background: MDSC are a heterogeneous population of immunosuppressive cells with potentially predictive implications in UC pts receiving CI. We hypothesized that MDSC populations may change after CI exposure. Methods: Serial peripheral blood samples were collected from mUC pts treated with CI. MDSC were measured in fresh unfractionated whole blood (WB) and in peripheral blood mononuclear cells (PBMC). MDSC were identified by flow cytometry in WB and defined as LinloCD33+/HLADR- [(T)otal MDSC]. MDSC subsets were defined as (G)ranulocytic (CD15+CD14-), (M)onocytic (CD15-CD14+), (I)mmature (CD15-CD14-), or CD11b+. MDSC populations were presented as % of live nucleated blood cells and as absolute numbers from WB. The Wilcoxon signed rank and rank sum tests were used to assess changes in MDSC populations while on CI. Results: 17 pts treated with CI (9 atezolizumab [A], 8 pembrolizumab [P]) had ≥ 2 MDSC samples for analysis. Median age at diagnosis was 71 (46-81), 12 men, 29% never smokers; 53% / 29% / 18% ECOG PS 0/1/2 and 59% visceral metastasis at the time of 1 st sample collection. 10 pts received CI as 1st line therapy (Tx) in metastatic setting; 7 pts received chemotherapy as 1st-line Tx for mUC (6 platinum-based, 1 docetaxel) and CI as 2nd-line Tx. In 16 pts with samples before 1 st dose, there was a relative decrease (median 36.3%, range -59.7 to +21.2) in PBMC % I-MDSCs between 1st and 2nd samples (p=0.06). Interestingly, PBMC %M-MDSC and %I-MDSC tended to increase compared to baseline in pts treated with P, while they tended to decrease in pts treated with A (Table). Conclusions: In this cohort of pts with mUC treated with CIs,MDSC changes differed based on CI (anti-PDL1 or anti-PD1). Further study in larger cohort with various prior Tx lines and longer follow up as well as correlations with Tx response, toxicity and outcomes are ongoing. [Table: see text]" @default.
• W2891638336 created "2018-09-27" @default.
• W2891638336 creator A5005282856 @default.
• W2891638336 creator A5014742901 @default.
• W2891638336 creator A5018140571 @default.
• W2891638336 creator A5025529463 @default.
• W2891638336 creator A5026717218 @default.
• W2891638336 creator A5031016267 @default.
• W2891638336 creator A5034073364 @default.
• W2891638336 creator A5044873389 @default.
• W2891638336 creator A5056587248 @default.
• W2891638336 creator A5066748171 @default.
• W2891638336 creator A5068011236 @default.
• W2891638336 creator A5069069312 @default.
• W2891638336 creator A5070016877 @default.
• W2891638336 creator A5079075086 @default.
• W2891638336 creator A5079994196 @default.
• W2891638336 creator A5085169485 @default.
• W2891638336 creator A5085460226 @default.
• W2891638336 creator A5085705349 @default.
• W2891638336 creator A5089516753 @default.
• W2891638336 creator A5090303753 @default.
• W2891638336 date "2017-05-20" @default.
• W2891638336 modified "2023-10-18" @default.
• W2891638336 title "Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI)." @default.
• W2891638336 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e16005" @default.
• W2891638336 hasPublicationYear "2017" @default.
• W2891638336 type Work @default.
• W2891638336 sameAs 2891638336 @default.
• W2891638336 citedByCount "1" @default.
• W2891638336 countsByYear W28916383362020 @default.
• W2891638336 crossrefType "journal-article" @default.
• W2891638336 hasAuthorship W2891638336A5005282856 @default.
• W2891638336 hasAuthorship W2891638336A5014742901 @default.
• W2891638336 hasAuthorship W2891638336A5018140571 @default.
• W2891638336 hasAuthorship W2891638336A5025529463 @default.
• W2891638336 hasAuthorship W2891638336A5026717218 @default.
• W2891638336 hasAuthorship W2891638336A5031016267 @default.
• W2891638336 hasAuthorship W2891638336A5034073364 @default.
• W2891638336 hasAuthorship W2891638336A5044873389 @default.
• W2891638336 hasAuthorship W2891638336A5056587248 @default.
• W2891638336 hasAuthorship W2891638336A5066748171 @default.
• W2891638336 hasAuthorship W2891638336A5068011236 @default.
• W2891638336 hasAuthorship W2891638336A5069069312 @default.
• W2891638336 hasAuthorship W2891638336A5070016877 @default.
• W2891638336 hasAuthorship W2891638336A5079075086 @default.
• W2891638336 hasAuthorship W2891638336A5079994196 @default.
• W2891638336 hasAuthorship W2891638336A5085169485 @default.
• W2891638336 hasAuthorship W2891638336A5085460226 @default.
• W2891638336 hasAuthorship W2891638336A5085705349 @default.
• W2891638336 hasAuthorship W2891638336A5089516753 @default.
• W2891638336 hasAuthorship W2891638336A5090303753 @default.
• W2891638336 hasConcept C121608353 @default.
• W2891638336 hasConcept C126322002 @default.
• W2891638336 hasConcept C143998085 @default.
• W2891638336 hasConcept C179185449 @default.
• W2891638336 hasConcept C203014093 @default.
• W2891638336 hasConcept C2777701055 @default.
• W2891638336 hasConcept C2780352672 @default.
• W2891638336 hasConcept C2780851360 @default.
• W2891638336 hasConcept C2911057145 @default.
• W2891638336 hasConcept C3019882237 @default.
• W2891638336 hasConcept C502942594 @default.
• W2891638336 hasConcept C55721878 @default.
• W2891638336 hasConcept C71924100 @default.
• W2891638336 hasConcept C8891405 @default.
• W2891638336 hasConceptScore W2891638336C121608353 @default.
• W2891638336 hasConceptScore W2891638336C126322002 @default.
• W2891638336 hasConceptScore W2891638336C143998085 @default.
• W2891638336 hasConceptScore W2891638336C179185449 @default.
• W2891638336 hasConceptScore W2891638336C203014093 @default.
• W2891638336 hasConceptScore W2891638336C2777701055 @default.
• W2891638336 hasConceptScore W2891638336C2780352672 @default.
• W2891638336 hasConceptScore W2891638336C2780851360 @default.
• W2891638336 hasConceptScore W2891638336C2911057145 @default.
• W2891638336 hasConceptScore W2891638336C3019882237 @default.
• W2891638336 hasConceptScore W2891638336C502942594 @default.
• W2891638336 hasConceptScore W2891638336C55721878 @default.
• W2891638336 hasConceptScore W2891638336C71924100 @default.
• W2891638336 hasConceptScore W2891638336C8891405 @default.
• W2891638336 hasLocation W28916383361 @default.
• W2891638336 hasOpenAccess W2891638336 @default.
• W2891638336 hasPrimaryLocation W28916383361 @default.
• W2891638336 hasRelatedWork W2494829332 @default.
• W2891638336 hasRelatedWork W2789664643 @default.
• W2891638336 hasRelatedWork W2792869479 @default.
• W2891638336 hasRelatedWork W2890001913 @default.
• W2891638336 hasRelatedWork W2910541326 @default.
• W2891638336 hasRelatedWork W2913802458 @default.
• W2891638336 hasRelatedWork W2916292904 @default.
• W2891638336 hasRelatedWork W2947663953 @default.
• W2891638336 hasRelatedWork W2947922688 @default.
• W2891638336 hasRelatedWork W2954314085 @default.
• W2891638336 hasRelatedWork W2955456037 @default.
• W2891638336 hasRelatedWork W3006479996 @default.
• W2891638336 hasRelatedWork W3029244862 @default.
• W2891638336 hasRelatedWork W3032621758 @default.
• W2891638336 hasRelatedWork W3032874360 @default.
• W2891638336 hasRelatedWork W3089214909 @default.
• W2891638336 hasRelatedWork W3140035148 @default.

• next